Insulet (PODD) Liabilities and Shareholders Equity (2010 - 2026)
Insulet's (PODD) quarterly Liabilities and Shareholders Equity came in at $3.0 billion in Q1 2026, down 15.07% YoY from $3.5 billion in Q1 2025, and down 6.37% on a QoQ basis from $3.2 billion in Q4 2025.
Insulet (PODD) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Insulet (PODD) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $3.0 billion in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 15.07% year-over-year to $3.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.7 billion (up 1.31% YoY) and the FY2025 annual result came in at $3.2 billion, up 3.33% from the prior year.
- Liabilities and Shareholders Equity retreated to $3.0 billion in Q1 2026, from $3.2 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $3.5 billion in Q1 2025 to a low of $2.1 billion in Q1 2022.
- A 5-year average of $2.7 billion and a median of $2.6 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity soared 34.04% — and 2026, when it declined 15.07%.
- Tracing PODD's Liabilities and Shareholders Equity over 5 years: stood at $2.3 billion in 2022, then climbed by 14.97% to $2.6 billion in 2023, then grew by 19.3% to $3.1 billion in 2024, then advanced by 3.33% to $3.2 billion in 2025, then fell by 6.37% to $3.0 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $3.0 billion (Q1 2026), $3.2 billion (Q4 2025), and $3.0 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.24 Bn | 193.64 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 128.63 Bn | 125.15 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 119.19 Bn | 109.97 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 73.51 Bn | 72.97 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 52.11 Bn | 47.85 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.64 Bn | 32.70 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 34.01 Bn | 31.90 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.40 Bn | 23.08 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.14 Bn | 22.65 Bn | 684.20 Mn | 10.74 Bn |
| 10 | Insulet | 10.35 Bn | 9.82 Bn | 562.60 Mn | 3.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.17 Bn |
| Mar 31, 2026 | 2.99 Bn |
| Dec 31, 2025 | 3.19 Bn |
| Sep 30, 2025 | 3.03 Bn |
| Jun 30, 2025 | 3.47 Bn |
| Mar 31, 2025 | 3.52 Bn |
| Dec 31, 2024 | 3.09 Bn |
| Sep 30, 2024 | 3.03 Bn |
| Jun 30, 2024 | 2.88 Bn |
| Mar 31, 2024 | 2.62 Bn |
| Dec 31, 2023 | 2.59 Bn |
| Sep 30, 2023 | 2.47 Bn |
| Jun 30, 2023 | 2.39 Bn |
| Mar 31, 2023 | 2.29 Bn |
| Dec 31, 2022 | 2.25 Bn |
| Sep 30, 2022 | 2.17 Bn |
| Jun 30, 2022 | 2.11 Bn |
| Mar 31, 2022 | 2.07 Bn |
| Dec 31, 2021 | 2.05 Bn |
| Sep 30, 2021 | 2.00 Bn |